
Asian food staple great for heart health — the ‘magic' is actually what's grown on it, expert says
Rice, rice, baby.
Not everyone knows that rice is a whole world that extends far beyond the white or brown on offer at your Chinese local.
But there's one particularly healthy variety that has managed to largely fly under the radar on this side of the pond.
3 Red yeast rice — used in traditional Chinese medicine — is known for its benefits for cardiovascular health.
MilletStudio – stock.adobe.com
'Red yeast rice is a brightly colored compound used in food and health products that is made by fermenting rice with a special type of yeast known as Monascus purpureus,' Dr. Amanda Frick, VP Medical Affairs at Thorne, told The Post.
'Red yeast rice has been used in traditional Chinese and western botanical medicine to maintain healthy cholesterol levels and support blood circulation.'
Research has shown this crimson product contains naturally occurring compounds that can help keep total and LDL cholesterol — as well as triglycerides, which are the most common type of fat in the body — at optimal levels.
It also contains a bunch of other, unpronounceable compounds — such as phytosterols beta-sitosterol, campesterol, and stigmasterol, and isoflavones — that can help keep your ticker running smoothly.
But the real secret sauce isn't what's in it so much as on it.
'Red yeast rice does get a lot more attention for its health benefits than your everyday white or brown rice. The 'magic' of red yeast rice isn't actually in the rice itself — it's in what's grown on it,' Frick said.
3 Research has shown this crimson product contains naturally occurring compounds that can help keep total and LDL cholesterol — as well as triglycerides, which are the most common type of fat in the body — at optimal levels.
Syda Productions – stock.adobe.com
'While white and brown rice provide a source of carbohydrates and fiber (depending on the rice type), they do not contain the additional nutrients like sterols and antioxidants that are found in red yeast rice.'
While it is a rice, it's more commonly found in powdered form or as a supplement — or in some fermented foods.
'There are foods like fermented tofu, red rice vinegar, and Japanese rice wine (sake) that include red yeast rice,' Frick said.
'Depending on the specific use in traditional Chinese medicine, it may be best prepared with other food ingredients or at a particular temperature.
'For uses in botanical medicine, it's often preferred to offer in a supplement form for consistent delivery of the bioactive compounds in red yeast rice.'
3 'While white and brown rice provide a source of carbohydrates and fiber (depending on the rice type), they do not contain the additional nutrients like sterols and antioxidants that are found in red yeast rice,' Frick said.
Pixel-Shot – stock.adobe.com
While the side effects tend to be relatively mild — think gas, tummy troubles, headache and reddish poop — red yeast rice isn't for everyone.
'As with any new dietary supplement, it's important to discuss starting red yeast rice with your health professional, who can determine if this is the right option for you, your lifestyle and your overall wellness plan,' she said.
'Women who are trying to become pregnant, pregnant or breastfeeding shouldn't take red yeast rice. Those who have kidney or liver disease also shouldn't take it. Additionally, it may interact with certain medications, supplements, alcohol and grapefruit.'
One other red flag: contamination. Some red yeast rice supplements can contain citrinin — a toxic byproduct of the fermentation process that can damage your kidneys or liver.
Red yeast rice might not be magic — but when it's properly made and thoughtfully used, it could be a powerful addition to your heart-health toolkit.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
11 hours ago
- Business Wire
Samsung Bioepis Enters into a Strategic Partnership with NIPRO for Commercialization of Multiple Biosimilars in Japan
INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. ('Samsung Bioepis') announced today that the company has entered into a license, development and commercialization agreement with NIPRO Corporation ('NIPRO') for multiple biosimilar candidates including SB17, ustekinumab biosimilar candidate, in Japan. 'This partnership marks an important step towards expanding our footprint in Japan. Biosimilars have a great potential to bring cost savings and widen access to treatments for healthcare systems, providers, and patients in Japan." Share Under the terms of the agreement, Samsung Bioepis will be responsible for the development, manufacture and supply of the medicines, while NIPRO will be responsible for commercialization of the medicines in Japan. 'This partnership marks an important step towards expanding our footprint in Japan. Biosimilars have a great potential to bring cost savings and widen access to treatments for healthcare systems, providers, and patients in Japan. We look forward to collaborating with NIPRO, a company renowned for its high-quality medical devices and healthcare solutions, to accelerate access to treatments in the Japanese market,' said Kyung-Ah Kim, President and Chief Executive Officer of Samsung Bioepis. 'We will continue to advance our development platform and innovate access to treatments for healthcare systems, payers, physicians, and patients around the world.' About Samsung Bioepis Co., Ltd. Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, and endocrinology. For more information, please visit: and follow us on social media – LinkedIn, X.

Epoch Times
14 hours ago
- Epoch Times
Sleep Better, Digest Better: How TCM Heals the Gut-Brain Connection
Do you struggle with bloating, acid reflux, or poor sleep at night? According to traditional Chinese medicine (TCM), your stomach may be the key to good slumber. TCM takes a holistic approach to restoring gut health and sleep by balancing your internal energy and calming the body from within. Healing Sleep and Digestion Through TCM Gastrointestinal (GI) issues like bloating, indigestion, acid reflux, and poor sleep are more than just nighttime nuisances—they may signal deeper imbalances in the body. Xin Chongyi, director of Taiwan's Xin Traditional Chinese Medicine Clinic, said in NTDTV's 'Health 1+1' program that TCM addresses these symptoms holistically, treating the root causes instead of just masking the pain. A Case Study A male patient in his 30s complained of chest pain from the front of his chest to the back, with the pain mainly residing near the diaphragm. He had sought help from several types of doctors, but had no significant improvement even with painkillers. He woke up each night after sleeping only one or two hours for two to three years. Xin found that the patient's chest pain originated from his stomach.
Yahoo
15 hours ago
- Yahoo
Japanese Lunar Lander Crashes In Second Failed Mission
A private Japanese lunar lander crashed during an attempted touchdown on the moon Friday. This marks the second failed mission for the Tokyo-based global lunar exploration company, ispace. The lander, named Resilience, lost communication less than two minutes before its scheduled landing in Mare Frigoris, a flat, crater-filled region on the moon's northern near side. A preliminary analysis indicated the laser system for measuring altitude malfunctioned, causing the lander to descend too fast. 'Based on these circumstances, it is currently assumed that the lander likely performed a hard landing on the lunar surface,' ispace said in a statement. 'This is the second time that we were not able to land. So we really have to take it very seriously,' CEO and founder Takeshi Hakamada told reporters, per Associated Press. He apologized to contributors and added that the mission was 'merely a stepping stone' to a larger lander planned for 2027 with NASA involvement. 'Engineers did everything they possibly could' to ensure success, he said minutes before the attempted landing. The 7.5-foot Resilience, launched in January from Florida on a SpaceX rocket, carried an 11-pound, four-wheeled rover named Tenacious, built by ispace's Luxembourg subsidiary. The rover, equipped with a high-definition camera and a shovel for NASA to collect lunar soil, was designed to operate for two weeks during the moon's daylight period. It also carried a toy-size Swedish-style red cottage, dubbed Moonhouse by artist Mikael Genberg, for placement on the lunar surface. The mission's $16 million payload included scientific instruments from Japanese firms and a Taiwanese university. The failure follows ispace's first lunar crash in 2023, caused by inaccurate altitude readings. 'Truly diverse scenarios were possible, including issues with the propulsion system, software or hardware, especially with sensors,' Chief Technology Officer Ryo Ujiie said at a press conference. Jeremy Fix, chief engineer for ispace's U.S. subsidiary, noted last month that the company, with a mission cost less than the first's $100 million, lacks 'infinite funds' and cannot afford repeated failures. 'We're not facing any immediate financial deterioration or distress because of the event,' CFO Jumpei Nozaki said, citing investor support. However, space shares faced heavy sell orders and were poised for a 29% drop. As of Thursday, their market capitalization was over 110 billion yen ($766 million). The crash marks another setback in the commercial lunar race, which began in 2019. U.S. firms Firefly Aerospace and Intuitive Machines achieved successful landings in March, though Intuitive's lander toppled in a crater. Japan's space agency, JAXA, landed its SLIM probe last year, joining Russia, the U.S., China, and India as the only nations with successful robotic lunar landings. 'Expectations for ispace have not faded,' Japanese Prime Minister Shigeru Ishiba posted on X, reported Reuters. Ispace remains committed to NASA's Artemis program, with plans for a third mission in 2027. 'NASA increasingly needs private companies to improve cost efficiency for key missions with limited budgets,' Hakamada said, referencing proposed U.S. budget cuts. Two U.S. companies, Blue Origin and Astrobotic Technology, aim for moon landings by year's end following Astrobotic's 2024 failure.